Therabest

Private

SeoulHealthcare & Life Scienceshttp://therabest.co.kr/

Last Round

Series C

Nov 19, 2021

Est. Valuation

$162.87M

Total Funding Raised

$22.05M

Company Overview

Therabest is a biotechnology company that develops next-generation immunotherapies using induced pluripotent stem cell (iPSC)-derived immune cells and nano-convergent drug delivery platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

natural killer cell therapyNK cell therapyinduced pluripotent stem cellsiPSCallogeneic cell therapyoff-the-shelf cell therapysolid tumor treatmentautoimmune cell therapycell therapy manufacturingbiotechnology R&Dclinical-stage biotechdrug licensingnext-gen immunotherapyoff-the-shelf medicinecell therapy platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Therabest Comparables

Compare Therabest with similar companies based on industry and business-model similarity.

Therabest comparables — related companies by embedding similarity
Company	Similarity	Market Cap
HebeCell	89%
Shoreline Biosciences	84%
Neukio Biotherapeutics	84%

View all Comparables

Therabest Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series C	Nov 19, 2021
Series B	Jun 21, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Youngbae Shin

CFO

Executive Team

Therabest Investors

Notable investors and investment history

Therabest investors
Investor	Rounds
DA Value Investment	Series C
Meritz Securities Co., Ltd.	Series C
DS Asset Management	Series C

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 20, 2026
Monthly visitors increased 171% MoM, reaching 3.8K.
Jan 6, 2026
Monthly visitors increased 52% MoM.

View all signals

Therabest Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Therabest Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Therabest's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeoul

Employee Range13

Year Founded2012

Last FundingNov 19, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.